Author

G. Kugener

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Tsherniak· 2 shared D. E. Root· 2 shared A. Conway· 1 shared A. Detappe· 1 shared A. J. Church· 1 shared A. L. Hong· 1 shared A. Letai· 1 shared A. Robichaud· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Tsherniak

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML

S. Lin, C. Larrue, B. K. A. Seong, N. V. Dharia, M. Kuljanin, C. Wechsler, G. Kugener, A. Robichaud, A. Conway, T. N. Mashaka, S. Mouche, B. Adane, J. Ryan, J. D. Mancias, S. T. Younger, , K. Stegmaier

This study identifies novel therapeutic targets for AML using an in vivo CRISPR screening platform, revealing SLC5A3 as a metabolic vulnerability and MARCH5 as an apoptosis regulator.

bioRxiv · Dec 28, 2020Cancer Biology

Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines

J. M. Dempster, J. Rossen, M. Kazachkova, J. Pan, G. Kugener, D. E. Root, A. Tsherniak

The paper describes updates to the Project Achilles processing pipeline for CRISPR screens in cancer cell lines, including quality control improvements and dependency score calculations.

bioRxiv · Jul 31, 2019 · PreprintCancer Biology

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala, W. J. Kim, B. D. Kynnap, M. B. Doshi, G. Kugener, G. J. Sandoval, T. P. Howard, J. Li, X. Yang, M. Tillgren, M. Ghandi, A. Sayeed, R. Deasy, , W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

bioRxiv · Dec 5, 2018Cancer Biology

Inhibition of mitochondrial ferredoxin 1 (FDX1) prevents adaptation to proteotoxic stress

P. Tsvetkov, A. Detappe, K. Cai, H. R. Keys, Z. Brune, W. Ying, P. Thiru, M. Reidy, G. Kugener, A. Tsherniak, S. Santagata, L. Whitesell, J. L. Markley, I. M. Ghobrial, S. Lindquist

This study identifies FDX1 inhibition as a strategy to prevent proteasome inhibitor resistance in cancer by targeting mitochondrial Fe-S cluster biosynthesis.

bioRxiv · Mar 24, 2018Cancer Biology